Loading organizations...
§ Private Profile · Sunnyvale, CA, USA
Biotech company develops small-molecule drugs for undruggable targets in oncology and autoimmune diseases using its IMTAC™ platform.
BridGene Biosciences is a San Jose, California-based biotechnology company that develops small-molecule drugs for traditionally undruggable targets using its proprietary chemoproteomic screening platform. The enterprise utilizes its IMTAC technology to screen covalent and non-covalent molecules against the entire proteome in live cells, advancing an internal clinical pipeline that includes the candidate BGC-515 for oncology and autoimmune diseases. The private company has secured significant capital to fund its research operations, including a $38.5 million Series B round in 2022 and a $28 million Series B+ financing led by Bayland Capital alongside Lapam Capital and Junson Capital. BridGene pursues strategic drug discovery collaborations with major pharmaceutical partners such as Takeda Pharmaceutical Company and recently appointed Nobel Laureate Bruce A. Beutler to its scientific advisory board. The organization was originally founded in 2018 by chief executive officer Ping Cao.
BridGene Biosciences has raised $78.5M across 3 funding rounds.
BridGene Biosciences has raised $78.5M in total across 3 funding rounds.
BridGene Biosciences has raised $78.5M across 3 funding rounds. Most recently, it raised $28.0M Series B in October 2025.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Oct 16, 2025 | $28M Series B | Yuexing SU | Grains Valley Venture Capital, Gtja Investment Group, Lapam Capital, Proxima Ventures | Announced |
| Jul 28, 2022 | $38.5M Series B | Dyee Capital, Junson Capital, Lapam Capital | — | Announced |
| May 5, 2021 | $12M Series A | Leilei Wang | Kaitai Capital, Pangu Capital, Takeda Ventures | Announced |
BridGene Biosciences has raised $78.5M in total across 3 funding rounds.
BridGene Biosciences's investors include Yuexing Su, Grains Valley Venture Capital, GTJA Investment Group, Lapam Capital, Proxima Ventures, Dyee Capital, Junson Capital, Leilei Wang, Kaitai Capital, Pangu Capital, Takeda Ventures.